| SYK |
Report |
Q2 2026 Revenue |
BEAT |
pred ~$6.65B vs. cons $6.56B |
MEDIUM |
| SYK |
Report |
Q2 2026 Organic Sales Growth |
BEAT |
pred ~10.2% vs. cons ~9.0% |
MEDIUM |
| SYK |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$3.58 vs. cons $3.47 |
MEDIUM |
| SYK |
Guide |
FY2026 Organic Sales Growth Guidance |
UNCHANGED |
guide ~8.0%-9.5% (reaffirmed) vs. cons ~8.7% (FY2026) |
MEDIUM |
| SYK |
Guide |
FY2026 Adjusted EPS Guidance |
UNCHANGED |
guide ~$14.90-$15.10 (reaffirmed) vs. cons ~$15.02 (FY2026) |
MEDIUM |
| SYK |
Guide |
2026-2028 Operating Margin Expansion Target |
UNCHANGED |
guide ~150bps+ cumulative vs. cons ~150bps (2026-2028) |
LOW |
| SYK |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| SYK |
Return |
5-day cumulative residual |
+0.7% (FADE) |
Stock has already rallied ~24% off May lows and sits back near pre-cyber-incident levels heading into the print, so a clean Q2 beat on revenue/EPS that merely reaffirms (rather than raises) FY26 guidance—likely given management's cautious, timing-driven framing and the still-unresolved margin recovery proof-point—offers little incremental fuel for out-year estimate revisions. Peer read-throughs this week (e.g., Humana selling off on an unchanged guide despite a beat) show the market is punishing 'reaffirm-only' outcomes after big pre-print rallies. Expect an initial pop on confirmation that demand wasn't permanently lost, followed by partial fade as investors lock in gains and sell-side models don't meaningfully raise 2H/FY27 numbers without an explicit guidance raise. |
LOW |